Literature DB >> 14973054

Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity.

Zifa Wang1, Tracy Cook, Sean Alber, Kaihong Liu, Imre Kovesdi, Simon K Watkins, Yoram Vodovotz, Timothy R Billiar, David Blumberg.   

Abstract

Nitric oxide is a potent radiosensitizer of tumors, but its use clinically is limited by serious side effects when administered systemically. We have demonstrated previously that gene transfer of the inducible nitric oxide synthase gene (iNOS) into colorectal cancer cells enhances radiation-induced apoptosis in vitro. The objectives of this study were to further characterize the effects of iNOS gene transfer on the radiosensitivity of human colorectal cancer cells in vitro and tumors grown in athymic nude mice. Adenoviral gene transfer of iNOS (AdiNOS) into human colorectal cancer cell lines (HCT-116 and SNU-1040 cells) significantly enhanced the effects of radiation with sensitizing enhancement ratios (0.1) of 1.65 and 1.6, respectively. The radiation enhancement induced by iNOS was associated with increased iNOS expression and nitric oxide production and prevented by L-NIO, an enzymatic inhibitor of iNOS. AdiNOS treatment of HCT-116 tumors combined with radiation (2 Gy x three fractions) led to a 3.4-fold greater (P < 0.005) tumor growth delay compared with radiation (RT) alone. AdiNOS plus RT also caused significant (P < 0.01) tumor regression with 63% of tumors regressing compared with only 6% of tumors treated with RT. AdiNOS plus RT significantly (P < or = 0.001) increased the percentage of apoptotic cells (22 +/- 4%) compared with either tumors treated with control vector plus RT (9 +/- 1%), AdiNOS alone (9 +/- 3%), or no treatment (2 +/- 1%). These radiosensitizing effects of AdiNOS occurred at low infection efficiency (4% of tumor infected), indicating a significant bystander effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973054     DOI: 10.1158/0008-5472.can-03-1307

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Radiation-induced bystander signalling in cancer therapy.

Authors:  Kevin M Prise; Joe M O'Sullivan
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Nitric oxide and cancer.

Authors:  Jordi Muntané; Manuel De la Mata
Journal:  World J Hepatol       Date:  2010-09-27

Review 3.  Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis.

Authors:  Jean-Pierre Pouget; Alexandros G Georgakilas; Jean-Luc Ravanat
Journal:  Antioxid Redox Signal       Date:  2018-03-22       Impact factor: 8.401

Review 4.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

5.  Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.

Authors:  Steven J Conrad; Mohamed El-Aswad; Esaw Kurban; David Jeng; Brian C Tripp; Charles Nutting; Robert Eversole; Charles Mackenzie; Karim Essani
Journal:  J Exp Clin Cancer Res       Date:  2015-02-19

6.  Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

Authors:  Heather Gibson; Stephanie Munns; Svend Freytag; Kenneth Barton; Jesse Veenstra; Ilham Bettahi; Jayne Bissonette; Wei-Zen Wei
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

7.  Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment.

Authors:  Cian M McCrudden; John W McBride; Joanne McCaffrey; Ahlam A Ali; Nicholas J Dunne; Vicky L Kett; Jonathan A Coulter; Tracy Robson; Helen O McCarthy
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-31       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.